Guardant Health Partners with Trial Library to Expand Access to Cancer Clinical Trials

Reuters12-11
Guardant Health Partners with Trial Library to Expand Access to Cancer Clinical Trials

Guardant Health Inc., a leading precision oncology company, has announced a strategic collaboration with Trial Library, an AI technology company focused on expanding access to oncology clinical trials. The partnership aims to increase equitable access to cancer clinical trials across the United States by integrating Guardant Health's genomic data with Trial Library's AI-powered patient matching and navigation platform. This initiative seeks to streamline the identification, referral, and enrollment of diverse and underserved patient populations into precision oncology clinical trials, helping providers offer new treatment opportunities and improving participation rates in cancer research.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251211844578) on December 11, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment